Switch theme
Sign up to access all valuation multiples
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
1996
n/a
LTM Revenue $425M
LTM EBITDA $160M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amoytop Biotech has a last 12-month revenue of $425M and a last 12-month EBITDA of $160M.
In the most recent fiscal year, Amoytop Biotech achieved revenue of $388M and an EBITDA of $139M.
Amoytop Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amoytop Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $289M | $388M | XXX | XXX | XXX |
| Gross Profit | $187M | $270M | XXX | XXX | XXX |
| Gross Margin | 65% | 70% | XXX | XXX | XXX |
| EBITDA | $96.4M | $139M | XXX | XXX | XXX |
| EBITDA Margin | 33% | 36% | XXX | XXX | XXX |
| Net Profit | $39.5M | $76.5M | XXX | XXX | XXX |
| Net Margin | 14% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Amoytop Biotech's stock price is CNY 78 (or $11).
Amoytop Biotech has current market cap of CNY 31.7B (or $4.4B), and EV of CNY 31.1B (or $4.3B).
See Amoytop Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $4.4B | XXX | XXX | XXX | XXX | $0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Amoytop Biotech has market cap of $4.4B and EV of $4.3B.
Amoytop Biotech's trades at 10.1x LTM EV/Revenue multiple, and 26.7x LTM EBITDA.
Analysts estimate Amoytop Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Amoytop Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 11.0x | XXX | XXX | XXX |
| EV/EBITDA | 30.9x | XXX | XXX | XXX |
| P/E | 38.4x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | 173.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAmoytop Biotech's NTM/LTM revenue growth is 32%
Amoytop Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Amoytop Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Amoytop Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Amoytop Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 68% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amoytop Biotech acquired XXX companies to date.
Last acquisition by Amoytop Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Amoytop Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Amoytop Biotech founded? | Amoytop Biotech was founded in 1996. |
| Where is Amoytop Biotech headquartered? | Amoytop Biotech is headquartered in China. |
| Is Amoytop Biotech publicy listed? | Yes, Amoytop Biotech is a public company listed on SHG. |
| What is the stock symbol of Amoytop Biotech? | Amoytop Biotech trades under 688278 ticker. |
| When did Amoytop Biotech go public? | Amoytop Biotech went public in 2020. |
| Who are competitors of Amoytop Biotech? | Similar companies to Amoytop Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amoytop Biotech? | Amoytop Biotech's current market cap is $4.4B |
| What is the current revenue of Amoytop Biotech? | Amoytop Biotech's last 12-month revenue is $425M. |
| What is the current EBITDA of Amoytop Biotech? | Amoytop Biotech's last 12-month EBITDA is $160M. |
| What is the current EV/Revenue multiple of Amoytop Biotech? | Current revenue multiple of Amoytop Biotech is 10.1x. |
| What is the current EV/EBITDA multiple of Amoytop Biotech? | Current EBITDA multiple of Amoytop Biotech is 26.7x. |
| What is the current revenue growth of Amoytop Biotech? | Amoytop Biotech revenue growth between 2023 and 2024 was 34%. |
| Is Amoytop Biotech profitable? | Yes, Amoytop Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
